The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. [electronic resource]
Producer: 20120501Description: 1791-2 p. digitalISSN:- 1528-0020
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Drug Evaluation, Preclinical
- Gene Duplication
- Humans
- Imidazoles -- pharmacology
- Leukemia, Myeloid, Acute -- drug therapy
- Molecular Targeted Therapy
- Mutant Proteins -- antagonists & inhibitors
- Mutation -- physiology
- Protein Kinase Inhibitors -- pharmacology
- Protein Structure, Tertiary -- genetics
- Proto-Oncogene Proteins c-pim-1 -- antagonists & inhibitors
- Pyridazines -- pharmacology
- Substrate Specificity -- genetics
- Tandem Repeat Sequences -- genetics
- fms-Like Tyrosine Kinase 3 -- antagonists & inhibitors
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.